Emerging Pharmaceutical Organization Awards $1.2 Million Study to eResearchTechnology for Cardiac Safety Monitoring and Informat
June 21 2004 - 9:05AM
PR Newswire (US)
Emerging Pharmaceutical Organization Awards $1.2 Million Study to
eResearchTechnology for Cardiac Safety Monitoring and Information
Distribution Services Thorough Phase I ECG Study to be Conducted
Over a 90-Day Period; Complements Later Phase Studies Already
Awarded to eRT PHILADELPHIA, June 21 /PRNewswire-FirstCall/ --
eResearchTechnology, Inc. (eRT) (NASDAQ:ERES), a leading provider
of centralized electrocardiographic (ECG) collection and
interpretation services, announced today that it has received an
agreement for about $1.2 million in cardiac safety monitoring and
services from an emerging pharmaceutical organization for one of
its drug candidates in clinical development. The agreement covers
an extensive Phase I study for which eRT is providing comprehensive
support including the provision, training and ongoing assistance
required for effective use of digital 12-lead Holter equipment
designed to facilitate 24-hour digital recording of cardiac safety
data that is subsequently provided to eRT for analysis. eRT will
perform digital collection, measurement, interpretation, review,
and distribution of cardiac safety data through its EXPeRT(R)
workflow enabled data handling technology, the first solution in
production that was designed explicitly to meet emerging
international regulatory guidance and technical standards. "We are
pleased to have been awarded this significant Thorough Phase I
Study just several months after winning two contracts for later
phase international trials for the same compound," said Scott
Grisanti, senior vice president of business development and chief
marketing officer at eRT. "Emerging market segment companies with
targeted therapies, such as this drug developer, are responding
well to eRT's ability to address cardiac safety requirements across
all phases of development and, in particular, eRT's Thorough Phase
I ECG Study experience and turnkey capabilities." Based in
Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/)
is a provider of technology and services to the pharmaceutical,
biotechnology and medical device industries on a global basis. The
company is a market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the
company's ability to obtain new contracts and accurately estimate
net revenues due to variability in size, scope and duration of
projects, and internal issues in the sponsoring client. The sponsor
may cancel this agreement at its sole discretion. As a result,
actual results may differ materially from any financial outlooks
stated herein. Further information on potential factors that could
affect the company's financial results can be found in the
company's Reports on Forms 10-K and 10-Q filed with the Securities
and Exchange Commission. DATASOURCE: eResearchTechnology, Inc.
CONTACT: Joan Sterlacci of eResearchTechnology, Inc.,
+1-908-203-6473; or Matt Hayden of Hayden Communications,
+1-858-456-4533, for eRT Web site: http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles